Julia Rock-Torcivia
ICU Medical (Nasdaq: ICUI) reported second quarter results that beat Wall Street expectations, upping its full-year guidance.
San Clemente, California–based ICE Medical, which specializes in IV therapy, infusion pumps and closed-system drug transfer devices, reported income of $19.1 million, or 76¢ per share, on revenue of $551.7 million for the three months ended June 30, 2026. The bottom line was only about half what it was in Q2 2025, while the top line was up a bit.
Adjusted to exclude one-time items, earnings per share were $2.37, beating analyst expectations of $1.91 on revenue of $533 million.
“Second quarter results were ahead of our expectations for Infusion Systems and generally in line with expectations for the remainder of the business,” CEO Vivek Jain said in a news release out after market close yesterday.
Infusion Systems had 12% organic growth, with a total revenue of $189.0 million, compared with $167.7 million for Q2 2025.
The company raised and narrowed FY2026 adjusted EBITDA guidance to $415 million to $435 million from $400 million to $430 million and adjusted EPS to $8.60 to $9.00 from $7.75 to $8.45, with full-year adjusted gross margin raised to 41.5%.
Needham & Co. analysts maintained their Buy rating on ICU Medical stock, noting that infusion systems pumped up growth.
ICUI shares were up more than 10% to $184.32 apiece by afternoon trading today.
